(From box) Dilute prior to use; for intravenous infusion only; single-use vial; discard unused portion
(From insert)
PERJETA is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.